Skip to content
Menu

Kyverna Therapeutics, Inc. KYTX

Full chart Compare
Set alert

Price alert · KYTX

All alert types
4.37 USD -0.11 (-2.46%)

Regular-session close

4.89 +0.52 +12.00%

After hours · Nov 19, 4:00 PM ET

4.30 Day range 4.62
4.30 52-week range 13.67
YTD
-53.51%
1 year
-46.90%

5D -0.48 (-9.47%)

4.604.8055.20WedThuFriMonTue4.59
Market cap
276.28M
EPS (ttm)
-2.75
Shares out
43.17M
Forward P/E
-1.00
YTD return
-53.51%
1-year return
-46.90%
50-day average
4.93
200-day average
10.72
Volume
823.76K
Avg volume
858.76K
Open
4.47
Previous close
4.48
Day's range
4.30 – 4.62
52-week range
4.30 – 13.67
Analysts
Buy
Price target
27.33 (+525.5%)

Key statistics

Enterprise value
-139.78M
Price / book
0.56
Free cash flow
-63.37M
Total cash
321.59M
Total debt
9.14M
Return on equity
-59.58%
Short % of float
6.34%

Fundamental scorecard

4 of 25 checks passed on KYTX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KYTX Revenue — quarterly 0
KYTX Net income — quarterly -41.94M
KYTX EPS — quarterly -0.68

Earnings

KYTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.77-0.80-0.03-3.90%
Aug 12, 2024Jun 1, 2024-0.70———
Aug 12, 2024Jun 1, 2024-0.70-0.67+0.03+4.29%
May 14, 2024Mar 1, 2024-0.88———
May 14, 2024Mar 1, 2024-0.88-1.12-0.24-27.27%

Upgrades / downgrades

KYTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2024HC Wainwright & Co.mainNeutralNeutral
Nov 15, 2024Wells FargomainOverweightOverweight
Oct 10, 2024UBSinit—Buy
Sep 19, 2024HC Wainwright & Co.reitNeutralNeutral
Aug 15, 2024HC Wainwright & Co.mainNeutralNeutral
Jul 31, 2024JP MorganmainOverweightOverweight

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on KYTX — it syncs with the Stock Master app.

Insider holders

KYTX insider holders
InsiderRelationLatest transactionDateShares held
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityPurchaseFeb 11, 20240
COHEN FREDERICK E. M.D. PH.D.Director and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 11, 20240
GILEAD SCIENCES INCBeneficial Owner of more than 10% of a Class of SecurityPurchaseFeb 11, 20244,126,120
JONES RYAN ALEXANDERChief Financial OfficerConversion of Exercise of derivative securityMay 27, 202443,950
NORTHPOND VENTURES III GP, L.L.C.FormerPurchaseFeb 11, 20240
SEIDENBERG BETH CDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 11, 20240

Institution ownership

KYTX institution ownership
Holder% heldSharesValueReported
Vida Ventures Advisors, LLC10.48%4,523,92417.73MSep 29, 2024
Bain Capital Life Sciences Investors, LLC7.80%3,368,37013.20MSep 29, 2024
Northpond Ventures, Llc7.54%3,255,42612.76MSep 29, 2024
JP Morgan Chase & Company5.53%2,387,3529.36MSep 29, 2024
Novo Holdings A/S4.29%1,850,0007.25MSep 29, 2024
Blackrock Inc.3.52%1,520,2615.96MSep 29, 2024

Fund ownership

KYTX fund ownership
Holder% heldSharesValueReported
JP Morgan Small Cap Growth Fund2.39%1,031,5464.04MSep 29, 2024
Vanguard Total Stock Market Index Fund1.47%633,8442.48MSep 29, 2024
iShares Russell 2000 ETF1.05%451,7591.77MOct 30, 2024
Franklin Strategic Series-Franklin Biotechnology Discove0.57%244,900960.01KJul 30, 2024
Vanguard Extended Market Index Fund0.54%232,962913.21KSep 29, 2024
Franklin Strategic Series-Franklin Small Cap Growth Fund0.52%224,100878.47KJul 30, 2024